NDC product
dihydroergotamine mesylate
NDC 36000-300 · Baxter Healthcare Corporation
Key facts
| Product NDC | 36000-300 |
|---|---|
| Proprietary name | dihydroergotamine mesylate |
| Nonproprietary name | dihydroergotamine mesylate |
| Substances | DIHYDROERGOTAMINE MESYLATE |
| Dosage form | INJECTION, SOLUTION |
| Route | INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS |
| Labeler | Baxter Healthcare Corporation |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Application number | ANDA216747 |
| Pharmacologic classes | Ergotamine Derivative [EPC], Ergotamines [CS] |
| Marketing start | Jan 7, 2025 |
| Listing certified through | Dec 31, 2026 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: